What is TechsoMed?
TechsoMed is at the forefront of medical imaging innovation, developing the BioTrace platform. This groundbreaking AI-based technology empowers physicians to accurately detect and visualize tissue viability during thermal ablation procedures, utilizing standard commercial ultrasound imaging. The platform's real-time image analysis capabilities are applicable across multiple clinical domains, including oncology for tumor ablation, cardiology for heart arrhythmia treatment, and pain management for radiofrequency neurotomy. The company's focus on enhancing diagnostic precision with AI positions it as a key player in the evolving landscape of medical technology.
How much funding has TechsoMed raised?
TechsoMed has raised a total of $9.6M across 2 funding rounds:
Other Financing Round
$2.6M
Series B
$7M
Other Financing Round (2019): $2.6M with participation from Screen Holdings, Axil Capital, JJDC, NextLeap Ventures, and AMIT-Technion
Series B (2021): $7M led by Axil Capital, Radianx Capital, Cobro Ventures, NextLeap Ventures, Magna Capital Partners, Yonjin Venture, JJDC, and JLABS companies
Key Investors in TechsoMed
Axil Capital
Axil Capital is an investment firm that likely focuses on providing capital for companies with high growth potential, particularly within the technology and healthcare sectors.
JJDC
JJDC (Johnson & Johnson Development Corporation) is the venture capital arm of Johnson & Johnson, specializing in investing in innovative healthcare technologies and companies that align with Johnson & Johnson's strategic interests in pharmaceuticals, medical devices, and consumer health.
Magna Capital Partners
Magna Capital Partners is an investment firm that emphasizes collaborative partnerships and a forward-looking approach to creating value, likely focusing on strategic investments in companies with strong growth potential and clear business goals.
What's next for TechsoMed?
With substantial enterprise-level backing and a recent strategic investment, TechsoMed is poised for accelerated growth and market penetration. The company's trajectory suggests a focus on scaling its operations, further developing its BioTrace platform, and expanding its clinical applications. Future endeavors will likely involve forging strategic partnerships within the healthcare ecosystem and potentially exploring new therapeutic areas where its AI-powered imaging technology can offer significant clinical advantages. This sustained financial support indicates a strong belief in TechsoMed's potential to revolutionize medical imaging and patient care.
See full TechsoMed company page
